NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Highly Specialised Technology Evaluation

Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Company	General
 Sarepta Therapeutics (Eteplirsen) Patient/carer groups Action Duchenne Action for Sick Children Alex's Wish Arthritis & Musculoskeletal Alliance Children's Society Contact a Family Disability Rights UK 	 All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products
 Duchenne Family Support Group Duchenne Now Duchenne UK Findacure Genetic Alliance UK Harrison's Fund Information Advice and Support Service Network Leonard Cheshire Disability Muscular Dystrophy UK Muslim Council of Britain 	 Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Alliance NHS Commercial Medicines Unit NHS Confederation NHS National Services Scotland Scottish Medicines Consortium Welsh Government Welsh Health Specialised Services Committee
 National Children's Bureau South Asian Health Foundation Specialised Healthcare Alliance Together for Short Lives 	Possible comparator companiesNoneRelevant research groups
 Professional groups Association of Anaesthetists Association of British Neurologists Association of Genetic Nurses & Counsellors Association of Respiratory Nurse Specialists Association of Surgeons of Great Britain and Ireland 	 British Myology Society Cochrane Cystic Fibrosis and Genetic Disorders Group Cochrane Musculoskeletal Group Duchenne Research Fund MRC Centre for Neuromuscular Diseases MRC Clinical Trials Unit Newcastle University John Walton

National Institute for Health and Care Excellence

Matrix for the evaluation of eteplirsen for treating Duchenne muscular dystrophy ID1003

Issue date: March 2018

Consultees Commentators (no right to submit or appeal) **British Cardiovascular Society** Centre for Muscular Dystrophy Research **British Dietetic Association** North Star Clinical Network British Heart Rhythm Society British Institute of Musculoskeletal National Institute for Health Research TREAT-NMD Medicine **British Orthopaedic Association** Associated Public Health Groups **British Paediatric Neurology** Public Health England Association Public Health Wales British Paediatric Respiratory Society British Society for Genetic Medicine British Society of Rehabilitation Medicine **British Thoracic Society** Chartered Society of Physiotherapy Physiotherapy Pain Association Primary Care Respiratory Society Royal College of Anaesthetists Royal College of General Practitioners Royal College of Nursing Royal College of Paediatrics and Child Health Royal College of Pathologists Royal College of Physicians Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine • The National Congenital Anomaly and Rare Disease Registration Service **UK Genetic Testing Network UK Clinical Pharmacy Association** Others Department of Health and Social Care NHS England

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against recommendations.

All non-company consultees are invited to make an evidence submission or submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the recommendations.

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the final evaluation document for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.